@article{TCR11309,
author = {Jaimee C. Eckers and Randall J. Kimple},
title = {Predictive biomarkers for prostate brachytherapy—not there yet},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 7},
year = {2016},
keywords = {},
abstract = {Brachytherapy has been used for the treatment of prostate cancer for nearly 100 years. Low dose rate brachytherapy, the permanent placement of radioactive seeds (e.g., Iodine-125 or Pallidium-103) within the prostate, is an effective treatment for men with clinically localized low-risk prostate cancer. Brachytherapy can also be delivered by temporarily inserting high energy radioactive isotopes (e.g., Iridium-192) into the prostate. This technique is referred to as high dose-rate brachytherapy. The ability of brachytherapy to directly deliver radiation within the prostate while limiting the dose delivered to surrounding normal tissues is a significant advantage of this treatment (1).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/11309}
}